Bajaj Healthcare jumps 13% on Cenobamate SEC nod 2026

Stock reaction after regulatory update

Bajaj Healthcare shares rallied 12.98% to ₹345 after the company said a Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) recommended a grant of approval for Cenobamate tablets. The move brought fresh attention to the company’s push into specialised central nervous system (CNS) therapies. The SEC’s recommendation is a key step, but it is not the final regulatory clearance. The company has said the last approval from CDSCO is still pending. Investors typically price such developments based on how quickly a product can move from regulatory milestones to commercial sales.

What the SEC recommendation covers

The SEC (Neurology and Psychiatry) has recommended permission for Bajaj Healthcare to manufacture and market Cenobamate tablets in six strengths. The company plans to produce the drug in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg. Bajaj Healthcare has said it is the first company in India to secure an SEC recommendation for Cenobamate tablets. The product is positioned as a next-generation anti-seizure medication. It is intended for the treatment of partial-onset seizures in adults.

Why Cenobamate matters in epilepsy treatment

Cenobamate is used in adult patients with partial-onset seizures. The regulatory milestone is significant because it signals progress toward expanding treatment choices in a specialised therapy area. For Bajaj Healthcare, the recommendation aligns with its stated aim of strengthening its CNS portfolio and building its specialty segment. From a business perspective, CNS therapies are typically more specialised than broad-based generics, and product entries are often linked to distinct regulatory pathways and commercialisation timelines. However, the company has not stated a launch date, and the final CDSCO approval is still awaited.

Management commentary and next steps

Anil Jain, Managing Director of Bajaj Healthcare, said the SEC recommendation marks a significant regulatory milestone and reflects the company’s progress in developing Cenobamate tablets. He also said the development reinforces the company’s commitment to expanding a portfolio of differentiated CNS therapies. The company indicated it intends to work closely with regulatory authorities to obtain the necessary approvals. Until CDSCO issues the final clearance, the product remains at the recommendation stage rather than a fully approved commercial product.

Market context: investors weigh milestone vs financials

Alongside the regulatory update, investors are also tracking the company’s recent financial performance. Bajaj Healthcare reported a net loss of ₹22.9 crore in Q4 FY26, compared with a profit of ₹11.2 crore in the same period a year earlier. Revenue in Q4 FY26 was reported at ₹143.6 crore, down 0.9%. The combination of a new regulatory milestone and a recent quarterly loss helps explain why market reactions can be mixed across sessions.

Recent trading reference and dividend disclosure

As a reference point cited in the update stream, on June 25, 2026, Bajaj Healthcare shares closed at ₹302.40 on the BSE, down 2.91%. The company has also declared a final dividend of ₹1.50 per share, subject to shareholder approval as mentioned in the coverage. Regulatory news can move prices sharply in the short term, but follow-through often depends on clarity on timelines for final approval and commercial rollout.

Tarapur operational unit sale: separate corporate action

Separately, Bajaj Healthcare approved the sale of its operational business unit in Tarapur to M/s Orchem Products. The consideration is up to ₹4.05 crore. The transaction was approved by the Board on June 23, 2026, and is expected to close by October 31, 2026. This deal is distinct from the Cenobamate regulatory milestone, but it is another corporate development investors may track in parallel.

Key facts at a glance

Why this regulatory step is material

The SEC recommendation is a meaningful checkpoint because it signals the regulator has reviewed the proposal and recommended permission, which can enable the next steps toward manufacturing and marketing once final clearance comes through. Bajaj Healthcare’s claim of being the first in India to reach this stage for Cenobamate tablets adds competitive context, though commercial advantage depends on execution after final approvals. The development also fits the company’s stated strategy of strengthening its CNS and specialty pharmaceuticals presence. At the same time, investors are likely to keep the company’s quarterly loss and revenue trend in view while assessing how much the new product can contribute once commercialised.

What to watch next

The immediate next milestone is the final regulatory approval from CDSCO, which the company says is still pending. Investors will also monitor any subsequent updates on manufacturing readiness and commercialisation plans for the six strengths. Separately, the company’s timeline to close the Tarapur unit sale by October 31, 2026 is another dated event that may feature in upcoming disclosures. For now, the market narrative remains anchored on the SEC recommendation and the path to final clearance.